Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients

Table 3

Bone metastasis-free survival (BMFS), disease-free (DFS), and overall survival (OS) for selected SNPs. Adjusted hazard ratios¹ (HRs), 95% confidence intervals (CIs), and corresponding 𝑃 values are shown.

SNP	Genotype	BMFS		DFS		OS
		HR (95% CI)	𝑃 value	HR (95% CI)	𝑃 value	HR (95% CI)	𝑃 value
rs1054016	GG	1 (reference)		1 (reference)		1 (reference)
	GT	1.06 (0.68, 1.65)	0.79	1.21 (0.88, 1.67)	0.24	1.22 (0.88, 1.69)	0.23
	TT	0.37 (0.17, 0.84)	0.02	0.91 (0.59, 1.40)	0.66	1.00 (0.65, 1.54)	1.00
rs1805034	TT	1 (reference)		1 (reference)		1 (reference)
	CT	0.73 (0.46, 1.17)	0.19	0.83 (0.60, 1.16)	0.29	0.88 (0.63, 1.24)	0.48
	CC	0.62 (0.34, 1.16)	0.13	0.91 (0.61, 1.35)	0.64	1.09 (0.73, 1.62)	0.67
rs35211496	CC	1 (reference)		1 (reference)		1 (reference)
	CT	0.90 (0.56, 1.45)	0.67	0.97 (0.70, 1.33)	0.84	1.01 (0.74, 1.39)	0.94
	TT	0.82 (0.20, 3.39)	0.79	1.19 (0.52, 2.73)	0.67	0.73 (0.27, 1.99)	0.54

1HRs were adjusted for age, BMI, tumor stage, nodal status, tumor type, grading, and ER.